Dr. Cheriparambil is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
310 Gaslight Blvd
Lufkin, TX 75904Phone+1 936-632-8787Fax+1 936-632-8832
Education & Training
- New York Presbyterian Hospital(Cornell Campus)/Coney Island HospitalFellowship, Cardiovascular Disease, 1997 - 2000
- New York-Presbyterian Brooklyn Methodist HospitalResidency, Internal Medicine, 1993 - 1996
- B.J. Medical College - University of PuneClass of 1981
Certifications & Licensure
- TX State Medical License 2000 - 2025
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012-2013
Publications & Presentations
PubMed
- 14 citationsAcute Reversible Cardiomyopathy and Thromboembolism After Cisplatin and 5-Fluorouracil Chemotherapy A Case ReportKuruvilla Mani Cheriparambil, Hemalatha Vasireddy, Anita Kuruvilla, Boris Gambarin, Majesh Makan
Angiology. 2000-10-01 - 31 citationsProlonged QRS duration (QRS ≥170 ms) and left axis deviation in the presence of left bundle branch block: A marker of poor left ventricular systolic function ?Mithilesh K. Das, Kuruvilla Cheriparambil, Ashwini Bedi, John Kassotis, C.V.R. Reddy
American Heart Journal. 2001-11-01 - 7 citationsCardioversion of atrial fibrillation with ibutilide: when is it most effective?Mithilesh K. Das, Kuruvilla Cheriparambil, Ashwini Bedi, John Kassotis, C.V.R. Reddy
Clinical Cardiology. 2002-09-01
Research History
- PRINCIPAL INVESTIGATOR: CLINICAL RESEARCH TRIALSPrincipal Investigator: 1) ( Livingston site) 2011 CACZ885M2301, CANTOS-- 2) Principal Investigator ( Livingston site) : 2011-2017 CLCZ696B2314, PARADIGM-HF 3) Principal Investigator: ( Livingston site ) recently concluded 2019 PARAGON study Entresto in preserved EF heart failure (CHFpEF)2011 - Present
Professional Memberships
- Member
Other Languages
- Hindi, Marathi, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: